Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?

Abstract excerpt

Urothelial cancer has long been known as a chemotherapy-sensitive disease. However, clinical trial data to date suggest a plateau to the magnitude of benefit from cytotoxic therapy alone. In spite of level 1 evidence supporting cisplatin-based chemotherapy for patients with muscle-invasive and metastatic urothelial cancer, underuse prevails among patients with localized disease and only a modest survival benefit...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy, Adjuvant
• Share to Cisplatin
• Share to Doxorubicin